Gut Flora Presents a Novel IBS Treatment Target : Modifying bacteria levels via antibiotics and probiotics may ease symptoms, but concerns persist.

Dr. Quigley is a consultant to and stock shareholder in Alimentary Health, which is developing B. infantis 35624 for commercial applications. Dr. Pimentel is a consultant to Salix Pharmaceuticals Inc., which markets rifaximin for the indication of traveler's diarrhea.

'I'm never going to be able to recommend antibiotics every 2 weeks to my patients for the rest of their lives.' DR. TALLEY